ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received ...

ROCKAWAY, NJ, Aug. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled ...

ROCKAWAY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the ...

gammaCore is cleared by the FDA for acute and preventive treatment of cluster headache and the acute treatment of migraine in adults. Previously, only 2 treatments were approved for acute treatment of ...

Outside the United States, gammaCore is used for multiple indications. In the United Kingdom, for instance, the National Institute for Health and Care Excellence has provided guidance for gammaCore ...

ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for ...

What if you could zap away the pain of a migraine or cluster headache attack with a device that fits in your hand? It’s not a gadget from a comic book — it’s gammaCore ® (nVNS), a noninvasive vagus ...

BASKING RIDGE, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use ...

ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed ...

The device is applied to the neck and transmits a mild electrical stimulation to the vagus nerve through the skin. The Food and Drug Administration (FDA) has approved the use of gammaCore (electroCore ...